New heart valve study aims to improve survival in aortic stenosis patients
NCT ID NCT07359898
First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study is testing the Navitor heart valve in 1000 people with severe aortic stenosis, a condition where the heart's main valve narrows. Participants receive the valve through a catheter, and researchers track survival and complications for one year. The goal is to see how well the valve works in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Navitor/Navitor Vision transcatheter aortic valve
- What this could lead to
- If successful, this could confirm that the Navitor valve is safe and effective for treating severe aortic stenosis in a broad patient population.
- What could go wrong
- This is an observational study without a comparison group, so results may not prove the valve is better than other options. Risks include complications from the valve implant procedure, such as bleeding or stroke.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE NATIVE AORTIC STENOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCCS Policlinico San Donato
RECRUITINGSan Donato Milanese, Lombardy, 20097, Italy